fbpx

15th Annual Congress on Controversies in Ophthalmology (COPHy 2024)

Find Out More

Sep 11, 2023

Ocular allergies and dry eye disease: Overlapping treatment options

Euin Cheong, OD

Dual-purpose therapeutics help patients with both conditions.

It is safe to claim that the gap between the treatment of allergic conjunctivitis and the therapy of dry eye illness is narrower than it has ever been. Although the 2 diseases have different pathophysiologies, etiologies, and demographics of individuals who are affected by them, the treatments for the 2 diseases overlap more than ever before.

Reproxalap for dry eye disease

Reproxalap (Aldeyra Therapeutics, Inc.) is a novel therapeutic candidate under research for the treatment of dry eye disease.1 It is a first-of-its-kind small molecule modulator of reactive aldehyde species (RASP), which is increased in inflammatory diseases of the body, including the eyes. Malondialdehyde (MDA), the most well-known RASP, has been linked to inflammatory ocular conditions such as autoimmune disorders, allergic conjunctivitis, and dry eye disease…..

Read more: https://www.optometrytimes.com/view/ocular-allergies-and-dry-eye-disease-overlapping-treatment-options?utm_source=sfmc&utm_medium=email&utm_campaign=09092023_OD_ESS-23-OTD0379_eNL_Essilor_EyeCon%20House%20ad&eKey=ZG9ubmFAbWFjdWxhcmhvcGUub3Jn

Source: Opotometry Times

Newsletter Sign-up

  • This field is for validation purposes and should be left unchanged.